CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

CRISPR Therapeutics' stock decline is likely ... and Transfusion-Dependent Beta Thalassemia (TDT) early on. Despite this similarity, the two companies are not similarly situated.

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

Shares of CRISPR Therapeutics CRSP have lost more than ... and transfusion-dependent beta-thalassemia (TDT) — in the United States and Europe. Both SCD and TDT indications have a significant ...

CRISPR Therapeutics CRSP is expected to report ... blood disorders — sickle cell disease and transfusion-dependent beta-thalassemia (TDT) — in the United States and Europe.

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...